Inhibition of the effector molecules and their signaling of the NLRP3 inflammasome has proven to be effective in treating CAPS and some NLRP3 inflammasome-driven chronic diseases. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.